Rare Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others), By Trait Type (Inherited v/s Acquired), By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others), By Technology (Next Generation Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays, Others), By Sample Type (DNA Sample, Blood Sample, Saliva Sample, Others), By End User (Hospitals & Clinics, Academic & Research Institutes, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Rare Disease Diagnostics Market was valued at USD 1.24 billion in 2024 and is expected to reach USD 2.87 billion by 2030 with a CAGR of 15.01% during the forecast period. The global market for Rare Disease Diagnostics is experiencing significant growth, driven by growing incidence of rare disorders, adoption of advanced technology, and increase in investments in R&D are impelling the growth of the market. Rare diseases or orphan diseases is any disease that affects a small percentage of the population. The other factors supporting the market’s growth are, increasing government initiatives for spreading awareness, expanding patient registry for rare disease, declining sequencing cost, rising geriatric population, growing launch of programs & new product development in rare disease diagnosis, and rise in research and development activities.

Key Market Drivers

Expanding Genomic Programs & Public Investment in Population-Scale Sequencing

Public investment in population genomics and national sequencing initiatives is a major structural driver of rare-disease diagnostics. Governments are funding large-scale programs (biobanks, newborn screening expansions, precision-medicine initiatives) that create both the data and the diagnostic pathways needed to identify rare genetic conditions at scale. For example, the U.S. National Institutes of Health’s All of Us program and similar national initiatives are purpose-built to generate diverse genomic datasets and clinical linkages; as these resources grow they lower the marginal cost and logistical friction of deploying whole-genome and exome sequencing in clinical care, which in turn increases diagnostic throughput for rare diseases. Public funding also supports centralized genomic laboratories, reimbursement pilots, and infrastructure that smaller health systems could not build alone — enabling more hospitals and national health services to offer sequencing for undiagnosed disease programs. In parallel, the World Health Organization and national public-health authorities have encouraged integrating genomics into routine care and surveillance, which normalizes investment in molecular diagnostic capacity. The combination of direct program funding, subsidized sequencing access, and public-sector registries means that more patients enter diagnostic pipelines earlier; as a result, diagnostic providers (reference labs, genomic centers, test developers) see growing demand and can amortize high fixed costs of sequencing and interpretation over larger caseloads. This public-backed scale is pivotal: it converts rare-disease genomics from boutique, out-of-pocket services into reimbursed, system-level diagnostics, accelerating market growth for validated tests, confirmatory assays, and interpretation services.

Policy Push for Newborn Screening & Early Detection Programs

Governments’ expansion of newborn screening (NBS) panels and national early-diagnosis policies is rapidly increasing the addressable market for rare-disease diagnostics. Newborn bloodspot screening historically targeted a handful of metabolic and endocrine disorders, but many countries are now adding conditions detectable by tandem mass spectrometry and genomic methods. Comprehensive reviews of global NBS activity show that dozens of countries are expanding panels and that coverage is increasing year-over-year, particularly in middle-income countries investing in maternal-child health. Early detection delivers clear public-health benefits — preventing irreversible disability, reducing lifetime care costs, and improving developmental outcomes — which makes NBS politically and economically attractive. Governments often underwrite the cost of screening infrastructure, laboratory networks, and follow-up programs, effectively guaranteeing volume for diagnostic labs and enabling the roll-out of confirmatory molecular tests, gene panels, and long-term registries. From a market perspective, policy action removes a major adoption barrier (who pays) and creates predictable, recurring demand for assays, consumables, and interpretive services. Moreover, expanded NBS drives innovation in cost-efficient confirmatory testing workflows (targeted sequencing, reflex tests, second-tier biochemical assays) that can be repurposed into pediatric and adult rare-disease diagnostic pathways—further enlarging the market.

Download Free Sample Report

Key Market Challenges

Diagnostic Odyssey, Fragmented Care Pathways & Low Awareness

A persistent, system-level challenge is the long “diagnostic odyssey” that many rare-disease patients face — years of appointments, misdiagnoses, and fragmented referrals before a definitive test is obtained. Surveys and registry analyses indicate that the average time to diagnosis often spans multiple years, with substantial geographic and demographic variation; this delay is driven by low disease awareness among primary-care providers, scarcity of specialty services in many regions, and inconsistent referral algorithms. For payers and health systems, the consequence is twofold: first, patients accrue high cumulative costs from repeated tests and ineffective treatments prior to diagnosis; second, late diagnosis often reduces the clinical value of available therapies and complicates reimbursement cases for expensive genetic tests. From a market perspective, the diagnostic odyssey depresses measured demand (many cases never reach testing), creates unpredictable demand timing, and forces diagnostic labs to invest in clinician education and outreach rather than purely scaling lab throughput. Efforts to improve awareness—decision-support tools for clinicians, triage checklists, and tele-referral systems—help but are unevenly implemented. Until front-line diagnosis and streamlined referral pathways are consistent across systems, the market will face a persistent gap between the true population prevalence of rare diseases and the number of patients reaching high-value molecular diagnostics.

Reimbursement Complexity, Small Patient Numbers & Economic Sustainability

Rare-disease diagnostics struggle with reimbursement complexity because tests are often costly, patient populations are small, and payers require strong evidence of clinical utility. Unlike common disease assays that accrue volume quickly, rare-disease tests must be justified on a per-case basis; payers and national health services frequently ask for evidence that a test will change management or reduce long-term costs. Generating that evidence is hard when the condition is ultra-rare and randomized trials are impractical. Moreover, heterogeneous reimbursement policies across countries create fragmented markets: a test reimbursed in one jurisdiction may be out-of-pocket elsewhere, limiting global scale. Governments are aware of the problem and in many places are piloting special pathways (coverage with evidence development, national rare-disease funds), but these programs are uneven and often limited by budget. For diagnostics companies and clinical labs, the economic challenge is real: high per-sample costs (sequencing, confirmatory assays, expert curation) combine with uncertain payer coverage, making pricing and commercial scaling difficult. The result is slowed investment in broad panels, constrained geographic rollout, and continued reliance on philanthropic or research funding to subsidize clinically important but low-volume tests. Policy innovations that create predictable reimbursement (national test formularies, bundled payments for rare-disease workups) would materially reduce this barrier—but until they are widespread, economic sustainability remains a major market constraint.

Key Market Trends

Shift from Single-Gene Tests to Exome/Genome + Centralized Interpretation Services

A major technological and commercial trend is the systemic move away from single-gene or small panel testing toward exome and whole-genome sequencing (WES/WGS) as first- or second-line diagnostics for rare disease. This is driven by dropping sequencing costs, improved bioinformatics, and the higher diagnostic yield of broad genomic assays for heterogenous phenotypes. Governments and public health programs are increasingly funding hospital-based or regional sequencing hubs that provide WES/WGS and centralized variant interpretation; this model concentrates technical expertise, standardizes pipelines, and improves variant curation quality. Centralized interpretation services—often supported by public-sector reference labs or academic consortia—allow economies of scale in the most labor-intensive step (clinical interpretation and variant classification) and produce higher-quality reports for clinicians. As a market trend, labs and diagnostic companies are therefore evolving from selling discrete test kits toward bundled services: sequencing + bioinformatics + expert curation + genetic counselling. This verticalization increases per-patient revenue while improving clinical utility and reducing downstream confirmatory testing. Public backing of centralized models also helps overcome capacity gaps in smaller hospitals and spreads best practices across regions, accelerating clinical adoption and making advanced diagnostics a predictable component of care for rare-disease patients.

Public–Private Data Sharing & Federated Models to Improve Variant Interpretation

Another powerful trend is the growth of public–private collaborations and federated data-sharing models to enlarge variant databases and improve interpretation—critical because variant pathogenicity calls depend on population frequency and phenotype linkage. Governments and public consortia are building national genotype–phenotype resources and enabling controlled research access; at the same time, diagnostic companies and academic centers contribute de-identified variant data to shared repositories. Federated approaches—where data stay behind local firewalls but can be queried for aggregate insights—are being promoted to reconcile privacy laws (e.g., GDPR) with the need for larger reference datasets. Better reference data reduces false positives/negatives and accelerates definitive diagnoses, increasing confidence among clinicians and payers. From a market perspective, companies that participate in interoperable networks gain improved interpretive power (hence higher diagnostic yield) and can justify reimbursement more readily; public investment in data governance, standard-setting, and APIs further catalyzes this trend. As federated sharing matures, diagnostic yields will rise, time-to-diagnosis will fall, and the clinical and economic case for broader genomic testing in rare disease will strengthen—feeding back into market growth for sequencing, analytics, and counselling services.

Segmental Insights

Indication Insights

Based on Indication, the hematology and oncology disease segment hold the largest market share, largely due to the growing prevalence of rare blood disorders and rare cancers that demand precise and advanced diagnostic approaches. According to the World Health Organization (WHO), over 400 million people globally are affected by rare diseases, and a significant proportion of these falls under the umbrella of rare hematological and oncological conditions. Disorders such as sickle cell anemia, thalassemia, hemophilia, myelodysplastic syndromes, and rare leukemias require specialized molecular and genetic testing, driving the demand for diagnostic innovations in this category. Governments and healthcare bodies worldwide are prioritizing early diagnosis of rare hematological and oncological diseases due to their life-threatening nature and the high costs associated with delayed detection. For instance, the U.S. National Cancer Institute (NCI) reports that about 25% of all cancers diagnosed each year in the U.S. are classified as rare cancers, affecting more than 200,000 patients annually. Similarly, in the European Union (EU), rare cancers account for 22% of all new cancer cases, making them a critical focus for rare diagnostic disease programs. The use of next-generation sequencing (NGS), liquid biopsies, cytogenetics, and advanced imaging techniques has significantly enhanced the detection and classification of these rare disorders, further reinforcing their dominance in the diagnostic market.

Download Free Sample Report

Regional Insights

Based on the region, North America holds the largest share of the Global Rare Disease Diagnostics Market, largely due to its advanced healthcare infrastructure, strong investment in genomic research, and well-established reimbursement frameworks. The United States is a central hub, supported by large-scale initiatives such as the NIH’s All of Us Research Program, which aims to collect health data from over one million participants to advance personalized medicine, including rare-disease diagnostics. Additionally, the U.S. Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS) have implemented policies to encourage the development and coverage of innovative diagnostic tests. The Rare Diseases Act and the Orphan Drug Act have also provided financial incentives for diagnostics and treatment development, stimulating the market ecosystem. According to the U.S. Government Accountability Office, more than 25–30 million Americans live with a rare disease, underscoring the vast need for accessible and accurate diagnostics.

Recent Developments

• In March 2025, MyOme, a frontrunner in clinical whole-genome analysis and polygenic risk assessment, launched its first rare disease diagnostic product at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. By leveraging WGS, MyOme aims to increase diagnostic accuracy and improve patient access to genetic testing.
• In February 2025, MedGenome introduced the #CarefortheRare campaign ahead of Rare Disease Day, focusing on raising awareness about undiagnosed inherited diseases and the importance of early genetic testing. The campaign featured a documentary highlighting the emotional and financial impact of rare diseases on families.
• In August 2024, Ambry Genetics, a subsidiary of REALM IDx, Inc., launched ExomeReveal, a multiomic exome sequencing test that integrates RNA analysis to enhance rare disease detection. Unlike conventional DNA-based sequencing, ExomeReveal performs functional RNA studies, resolving variants of uncertain significance and improving diagnostic accuracy. Initial trials showed clinically meaningful results in 1 in 50 patients, with an additional 5% benefiting from long-term genomic reanalysis via the Ambry Patient for Life program.

Key Market Players

• Agilent Technologies, Inc.
• Illumina, Inc.
• QIAGEN NV
• PerkinElmer, Inc.
• Quest Diagnostics, Inc.
• CENTOGENE N.V.
• 23andMe, Inc.
• 3billion, Inc.
• Eurofins Scientific SE
• Invitae Corporation

Report Scope:

In this report, the Global Rare Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Rare Disease Diagnostics Market, By Indication:

o   Gastroenterology Disease

o   Endocrine & Metabolism Disorders Disease

o   Cardiovascular Disorders

o   Hematology & Oncology Disease

o   Others

• Rare Disease Diagnostics Market, By Trait Type:

o   Inherited

o   Acquired

• Rare Disease Diagnostics Market, By Test Type:

o   Genetic Tests

o   General Lab Tests

o   Diagnostic Imaging

o   Others

• Rare Disease Diagnostics Market, By Technology:

o   Next Generation Sequencing

o   Whole Genome Sequencing

o   Whole Exome Sequencing

o   Microarrays

o   Others

• Rare Disease Diagnostics Market, By Sample Type:

o   DNA Sample

o   Blood Sample

o   Saliva Sample

o   Others

• Rare Disease Diagnostics Market, By End User:

o   Hospitals & Clinics

o   Academic & Research Institutes

o   Others

• Rare Disease Diagnostics Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Rare Disease Diagnostics Market.

Available Customizations:

Global Rare Disease Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Rare Disease Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]